The role of ESR1 mutations in breast cancer: Implications for diagnosis, treatment, and the development of companion diagnostics

ESR1 mutations fuel resistance to hormone therapy in HR+ metastatic breast cancer

ZeptoMetrix delves into the mechanisms and prevalence of ESR1 mutations in breast cancer, exploring their clinical implications and the role of companion diagnostics. It further highlights the essential role of robust controls in mutation detection assays to ensure precision and reliability, ultimately enhancing patient outcomes through personalized medicine. Ongoing research and innovation in ESR1 targeted therapies and diagnostic technologies is needed, as advancements in these fields can potentially transform breast cancer treatment.